

Focus on Patient & Product Quality as the foundation for Data Integrity

Doreen Newhouse, Global Head, Sandoz Data Integrity Office *presented by*

James Mann, Head Data Integrity Program Management, Pharma

Barcelona, Oct 27, 2015




FDA Warning Letters about DI to Indian suppliers

Warning Letter Issued To	Date Warning Letter Issued	
Apotex Research Private Limited	01/30/2015	
Micro Labs Limited	01/09/2015	
Cadila Pharmaceuticals Limited	10/15/2014	
Marck Biosciences Ltd.	07/08/2014	
Apotex Pharmachem India Pvt Ltd.	06/17/2014	
Sun Pharmaceutical Industries	05/07/2014	
Canton Laboratories Private Limited	02/27/2014	
USV Limited	02/06/2014	
Wockhardt Limited	11/25/2013	
Agila Specialties Private Limited	09/09/2013	
Posh Chemicals Private Limited	08/02/2013	
Aarti Drugs Limited	07/30/2013	



EU regulators are taking strong action on DI




EMA Recommends Suspending Drugs over GVK Data Integrity Issues Posted 23 January 2015

More than 700 Products Recommended for Suspension



Data Integrity: what are we aiming for?





Performance & business pressure


Lack of awareness or capability

Root Causes

DI not fully integrated into Culture

Inadequate processes & technology





or capability

Root Causes

DI not fully integrated into Culture

Inadequate processes & technology

4.2 3,6 3,0 2,4





Performance & business pressure

Lack of awareness or capability

Root Causes

DI not fully integrated into Culture

Inadequate processes & technology





Performance & business pressure

Lack of awareness or capability

Root Causes

DI not fully integrated into Culture

Inadequate processes & technology





Performance & business pressure

Lack of awareness or capability

DI not fully integrated into Culture


Root

Causes

Inadequate processes & technology

2	GUEST	
6	1234	

NOVARTIS



Note: bias based on reporting



Four vital steps towards Data Integrity





Four vital steps towards Data Integrity






What education? What communication?









Examples of how we're communicating the risksand related impact!







Culture and education is the foundation for a strong Data Integrity mindset



Data Integrity, A Novartis Approach | Pharma Process Barcelona 27 October | D.Newhouse/J.Mann | Business Use Only

U NUVAKTIS

....so **mindset shift** to strengthen understanding of Data Integrity and impact on patients safety and product quality are key.

Education and consistent communication ensure:

- A common understanding
- Awareness of impact
- Ownership
- Leadership support



Any further activities can now build on this to ensure sustainability!




Four vital steps towards Data Integrity





Understand risks: known risk areas

Understand current risks





Archiving raw data? Audit trail? Segregation of duty?

STAND-ALONE




INSECURE ID



DLCPM*: understand risks, optimize processes *Data Lifecycle Process Mapping

Mitigate risks






Understand risks through DLCPM*

*Data Lifecycle Process Mapping

Mitigate risks





Four vital steps towards Data Integrity





Processes & systems: prevent risks from emerging

Mitigate risks

Define minimum Requirements

EXAMPLE

Create explicit requirements for all types of systems, including manual, automated/IT and hybrids.

Define IT & Process Standards

EXAMPLES

Segregate duties so that those who generate data cannot change it. Require data storage & archiving.

Implement Requirements


EXAMPLE

Lock down systems with individual logins, enable audit trails, apply the "Four Eye" principle.

25 days	Mon 31.08.09
10 days	Fri 25.09.09



Define IT and technology strategy






Four vital steps towards Data Integrity





Establish governance structure






Detect	Identify	Learn	Monitor
What's the DI issue?	What is the root cause?	How will we fix it across the company?	Is the fix effective? (Right trend?)
INDIVIDUAL ISSUE		HOLISTIC RESPONSE	




Collaborate to leverage lessons learned






Collaborate to leverage lessons learned






Learn lessons from the industry and regulators






As awareness rises, we'll see more issues at first





Priorities: patient and product quality









- How are you prioritizing your DI initiative / activities?
- Where have you chosen to start? Why?

